163 related articles for article (PubMed ID: 26983743)
1. Identification and Analysis of Antiviral Compounds Against Poliovirus.
Leyssen P; Franco D; Tijsma A; Lacroix C; De Palma A; Neyts J
Methods Mol Biol; 2016; 1387():325-38. PubMed ID: 26983743
[TBL] [Abstract][Full Text] [Related]
2. A case for developing antiviral drugs against polio.
Collett MS; Neyts J; Modlin JF
Antiviral Res; 2008 Sep; 79(3):179-87. PubMed ID: 18513807
[TBL] [Abstract][Full Text] [Related]
3. Potential use of antiviral agents in polio eradication.
De Palma AM; Pürstinger G; Wimmer E; Patick AK; Andries K; Rombaut B; De Clercq E; Neyts J
Emerg Infect Dis; 2008 Apr; 14(4):545-51. PubMed ID: 18394270
[TBL] [Abstract][Full Text] [Related]
4. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1.
Tijsma A; Thibaut HJ; Spieser SA; De Palma A; Koukni M; Rhoden E; Oberste S; Pürstinger G; Volny-Luraghi A; Martin J; Marchand A; Chaltin P; Neyts J; Leyssen P
Antiviral Res; 2014 Oct; 110():1-9. PubMed ID: 25043639
[TBL] [Abstract][Full Text] [Related]
5. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond.
Thys B; De Palma AM; Neyts J; Andries K; Vrijsen R; Rombaut B
Antiviral Res; 2008 Jun; 78(3):278-81. PubMed ID: 18294707
[TBL] [Abstract][Full Text] [Related]
6. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.
Duintjer Tebbens RJ; Pallansch MA; Thompson KM
BMC Infect Dis; 2015 Sep; 15():379. PubMed ID: 26382043
[TBL] [Abstract][Full Text] [Related]
7. Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Jul; 60(25):846-50. PubMed ID: 21716199
[TBL] [Abstract][Full Text] [Related]
8. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
Orenstein WA;
Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
[TBL] [Abstract][Full Text] [Related]
9. Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073.
Kouiavskaia DV; Dragunsky EM; Liu HM; Oberste MS; Collett MS; Chumakov KM
Antivir Ther; 2011; 16(7):999-1004. PubMed ID: 22024515
[TBL] [Abstract][Full Text] [Related]
10. New small-molecule inhibitors effectively blocking picornavirus replication.
Ford Siltz LA; Viktorova EG; Zhang B; Kouiavskaia D; Dragunsky E; Chumakov K; Isaacs L; Belov GA
J Virol; 2014 Oct; 88(19):11091-107. PubMed ID: 25008939
[TBL] [Abstract][Full Text] [Related]
11. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
Pliaka V; Kyriakopoulou Z; Markoulatos P
Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
[TBL] [Abstract][Full Text] [Related]
12. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds.
Rhoden E; Liu HM; Wang-Chern SW; Oberste MS
Antiviral Res; 2013 May; 98(2):186-91. PubMed ID: 23499651
[TBL] [Abstract][Full Text] [Related]
13. Antipoliovirus activity and mechanism of action of 3-methylthio-5-phenyl-4-isothiazolecarbonitrile.
Garozzo A; Stivala A; Tempera G; Castro A
Antiviral Res; 2010 Dec; 88(3):325-8. PubMed ID: 20955736
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-555 has potent antiviral properties against poliovirus.
Shim BS; Wu W; Kyriakis CS; Bakre A; Jorquera PA; Perwitasari O; Tripp RA
J Gen Virol; 2016 Mar; 97(3):659-668. PubMed ID: 26683768
[TBL] [Abstract][Full Text] [Related]
15. The antiviral compound 5-(3,4-dichlorophenyl) methylhydantoin inhibits the post-synthetic cleavages and the assembly of poliovirus in a cell-free system.
Verlinden Y; Cuconati A; Wimmer E; Rombaut B
Antiviral Res; 2000 Oct; 48(1):61-9. PubMed ID: 11080541
[TBL] [Abstract][Full Text] [Related]
16. [Circulation of the poliovirus in endemic zones with children vaccinated by the oral polio vaccine].
Gouandjika I; Rakoto Andrianarivelo M; Akoua-Koffi C; Zeller H; Ehouman A; Morvan JM
Bull Soc Pathol Exot; 2000 Jul; 93(3):198-201. PubMed ID: 11030057
[TBL] [Abstract][Full Text] [Related]
17. Dominant drug targets suppress the emergence of antiviral resistance.
Tanner EJ; Liu HM; Oberste MS; Pallansch M; Collett MS; Kirkegaard K
Elife; 2014 Nov; 3():. PubMed ID: 25365453
[TBL] [Abstract][Full Text] [Related]
18. [Intense campaign for vaccination with the oral polio vaccine: what are the repercussions on the enterovirus world?].
Delpeyroux F; Guillot S; Szendröi A; Balanant J; Caro V; Cuervo N; Chevaliez S; Dahourou G; Crainic R
Bull Soc Pathol Exot; 2000 Jul; 93(3):193-7. PubMed ID: 11030056
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of Poliovirus Resistance to Host Phosphatidylinositol-4 Kinase III β Inhibitor.
Arita M
ACS Infect Dis; 2016 Feb; 2(2):140-8. PubMed ID: 27624965
[TBL] [Abstract][Full Text] [Related]
20. Interrupting wild poliovirus transmission using oral poliovirus vaccine: environmental surveillance in high-risks area of India.
Chowdhary R; Dhole TN
J Med Virol; 2008 Aug; 80(8):1477-88. PubMed ID: 18551602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
